Could a bone drug help fight ovarian cancer?

NCT ID NCT05053750

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether adding zoledronic acid (a bone-strengthening drug) to standard chemotherapy and a targeted therapy can help women with ovarian cancer that no longer responds to platinum-based treatment. The study involves 14 participants and focuses on measuring immune cells in tumors. It is an early-phase trial, so the main goal is to see how the body responds, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zoledronic acid (added to paclitaxel and bevacizumab)
What this could lead to
If it works, this could point toward a new combination therapy for hard-to-treat ovarian cancer that has stopped responding to platinum-based chemo.
What could go wrong
This is a very early, small pilot study with only 14 participants. It is designed mainly to measure immune cell counts, not to prove the treatment works. The added drug may cause side effects like bone pain or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.